Jacobson M A, Forma F M, Buenaga R F, Hofmann K J, Schultz L D, Gould R J, Friedman P A
Department of Pharmacology, Merck Sharp and Dohme Research Laboratories, West Point, PA 19486.
Gene. 1989 Dec 28;85(2):511-6. doi: 10.1016/0378-1119(89)90445-9.
A synthetic gene coding for a platelet aggregation inhibitor, echistatin (ECS), was inserted into a Saccharomyces cerevisiae expression vector utilizing the alpha-mating factor pre-pro leader sequence and galactose-inducible promoter, GAL10. Cleavage of the pre-pro leader sequence in vivo results in the secretion of a properly processed recombinant ECS with the native N-terminal glutamic acid residue. Recombinant ECS was recovered from yeast supernatants and purified by reverse phase high performance liquid chromatography. Recombinant ECS expressed and purified from yeast was identical to native ECS in its ability to inhibit platelet aggregation.